Go Pro
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel Free KALV Stock Alerts

This company has been marked as potentially delisted and may not be actively trading.

KalVista Pharmaceuticals (KALV) Earnings Date, Estimates & Call Transcripts

KalVista Pharmaceuticals logo
Compare

KalVista Pharmaceuticals Earnings Summary

KalVista Pharmaceuticals released Q1 2026 earnings on May 14, 2026, reporting an EPS of -$0.43, which missed the consensus estimate of -$0.38 by $0.05. Quarterly revenue was reported to be $40.86 million, above the consensus estimate of $39.03 million. With a trailing EPS of -$3.46, KalVista Pharmaceuticals' earnings are expected to grow next year, from ($1.19) to $0.75 per share.

Q1 2026 Earnings Resources

Powered by Quartr
Latest Q1
Earnings Date
May. 14Estimated
Consensus EPS
(May. 14)
-$0.38
Actual EPS
(May. 14)
-$0.43 Missed By -$0.05
Actual Revenue
(May. 14)
$40.86M
Get KalVista Pharmaceuticals Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on KalVista Pharmaceuticals and other key companies, straight to your inbox.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Estimated and Actual Earnings Data

KALV Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

KALV Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

KalVista Pharmaceuticals Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20262-$0.69-$0.49-$0.59
Q2 20262-$0.42-$0.42-$0.42
Q3 20262-$0.39-$0.23-$0.31
Q4 20262-$0.29-$0.01-$0.15

KalVista Pharmaceuticals Earnings History by Quarter

Export
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
5/14/2026Q1 2026-$0.3763-$0.43 -$0.0538-$0.43$39.03M$40.86M
11/10/2025Q3 2026-$0.96-$0.92+$0.04-$0.92$6.03M$13.69M
9/11/2025Q1 2026-$0.91-$1.12 -$0.21-$1.12$1.97M$1.43M
7/10/2025Q4 2025-$0.83-$3.69 -$2.86-$0.99$4.20M-
12/5/2024Q2 2025-$0.92-$0.91+$0.01-$0.91--
9/5/2024Q1 2025-$0.91-$0.87+$0.04-$0.87--

KalVista Pharmaceuticals Earnings - Frequently Asked Questions

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its quarterly earning data on Thursday, May 14, 2026. Learn more on KALV's earnings history.

In the previous quarter, KalVista Pharmaceuticals (NASDAQ:KALV) missed the analysts' consensus estimate of ($0.38) by $0.05 with a reported earnings per share (EPS) of ($0.43). Learn more on analysts' earnings estimate vs. KALV's actual earnings.

KalVista Pharmaceuticals (NASDAQ:KALV) has a recorded annual revenue of $1.43 million.

KalVista Pharmaceuticals (NASDAQ:KALV) has a recorded net income of -$109.52 million. KALV has generated -$3.46 earnings per share over the last four quarters.

KalVista Pharmaceuticals' earnings are expected to grow from ($1.19) per share to $0.75 per share in the next year.

Related Companies
Earnings Tools

Earnings data for NASDAQ:KALV is sourced from Fiscal.ai, with the most recent quarter reported on 5/14/2026. New results are added as companies report their earnings.
From Our Partners
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...
Paradigm Press | Sponsoredtc pixel
Ray Dalio: Buy Gold. Get Paid.
Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...
Investors Alley | Sponsoredtc pixel
A Dark Day Is Coming to America
Keith Kaplan, CEO of TradeSmith, has spent more than $17 million studying AI since 2022. He says a major shift...
TradeSmith | Sponsoredtc pixel
Elon admits defeat
Elon Musk just called Anthropic the clear leader in AI, admitting its Mythos model surpasses anything he's bui...
Weiss Ratings | Sponsoredtc pixel
The dollar just broke
Bloomberg research shows the U.S. dollar's share of global reserves has fallen to the lowest level this centur...
Porter & Company | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
Gold Miners Post Record Cash Flow Even as Prices Pull Back
The four largest gold miners are generating record free cash flow, even with gold pulling back from recent hig...
Golden Portfolio | Sponsoredtc pixel